411,701 Shares in LifeStance Health Group, Inc. $LFST Bought by TD Waterhouse Canada Inc.

TD Waterhouse Canada Inc. bought a new stake in shares of LifeStance Health Group, Inc. (NASDAQ:LFST) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 411,701 shares of the company’s stock, valued at approximately $4,908,000.

Several other hedge funds have also bought and sold shares of the stock. Assetmark Inc. grew its stake in LifeStance Health Group by 17.0% in the 1st quarter. Assetmark Inc. now owns 9,419 shares of the company’s stock worth $60,000 after buying an additional 1,367 shares in the last quarter. Everhart Financial Group Inc. increased its holdings in shares of LifeStance Health Group by 1.3% in the 3rd quarter. Everhart Financial Group Inc. now owns 112,844 shares of the company’s stock worth $1,358,000 after buying an additional 1,435 shares during the last quarter. Allworth Financial LP increased its holdings in shares of LifeStance Health Group by 7.7% in the 2nd quarter. Allworth Financial LP now owns 26,532 shares of the company’s stock worth $284,000 after buying an additional 1,889 shares during the last quarter. Diversified Trust Co raised its position in shares of LifeStance Health Group by 14.8% during the 1st quarter. Diversified Trust Co now owns 21,532 shares of the company’s stock valued at $137,000 after buying an additional 2,770 shares in the last quarter. Finally, IFP Advisors Inc raised its position in shares of LifeStance Health Group by 316.5% during the 2nd quarter. IFP Advisors Inc now owns 3,694 shares of the company’s stock valued at $40,000 after buying an additional 2,807 shares in the last quarter. 85.50% of the stock is currently owned by institutional investors.

LifeStance Health Group Stock Up 0.3%

Shares of LFST opened at $11.77 on Tuesday. The firm has a market cap of $4.50 billion, a P/E ratio of 90.55 and a beta of 1.24. The stock has a 50 day simple moving average of $12.38 and a two-hundred day simple moving average of $10.03. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.38 and a quick ratio of 1.38. LifeStance Health Group, Inc. has a 1 year low of $4.77 and a 1 year high of $13.56.

LifeStance Health Group (NASDAQ:LFST) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.06 EPS for the quarter, topping the consensus estimate of $0.03 by $0.03. The firm had revenue of $435.35 million for the quarter, compared to the consensus estimate of $414.58 million. LifeStance Health Group had a net margin of 3.19% and a return on equity of 3.39%. The business’s revenue was up 26.1% compared to the same quarter last year. During the same period last year, the firm posted ($0.01) earnings per share. On average, analysts forecast that LifeStance Health Group, Inc. will post 0.16 earnings per share for the current fiscal year.

Insider Activity

In other news, CTO Vukasin Paunovich sold 42,067 shares of the company’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $12.87, for a total value of $541,402.29. Following the completion of the sale, the chief technology officer owned 205,379 shares of the company’s stock, valued at approximately $2,643,227.73. This represents a 17.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Lisa Miller sold 47,912 shares of the stock in a transaction on Monday, August 10th. The shares were sold at an average price of $10.85, for a total transaction of $519,845.20. Following the transaction, the chief operating officer directly owned 281,289 shares in the company, valued at approximately $3,051,985.65. This represents a 14.55% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 13,777,580 shares of company stock valued at $146,433,781. Corporate insiders own 3.50% of the company’s stock.

Analyst Upgrades and Downgrades

LFST has been the subject of several research reports. Weiss Ratings upgraded shares of LifeStance Health Group from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 11th. Barclays increased their target price on LifeStance Health Group from $13.00 to $15.00 and gave the company an “overweight” rating in a research note on Thursday, September 10th. KeyCorp raised their price target on LifeStance Health Group from $13.00 to $15.00 and gave the company an “overweight” rating in a research report on Monday, October 5th. BTIG Research lifted their price target on LifeStance Health Group from $16.00 to $18.00 and gave the stock a “buy” rating in a research note on Wednesday, August 19th. Finally, Canaccord Genuity Group lifted their price target on LifeStance Health Group from $13.00 to $15.00 and gave the stock a “buy” rating in a research note on Wednesday, September 9th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, LifeStance Health Group presently has an average rating of “Moderate Buy” and a consensus target price of $13.12.

LifeStance Health Group Company Profile

LifeStance Health Group, Inc is a provider of outpatient behavioral health services in the United States. Through a network of clinicians and care centers, the company offers mental health care through in-person appointments and telehealth visits.

LifeStance’s services include individual, couples and family therapy; psychiatric evaluation and medication management; psychological and neuropsychological testing; and treatment for conditions such as depression, anxiety, attention-deficit/hyperactivity disorder, bipolar disorder, post-traumatic stress disorder and other behavioral health concerns.